Health Canada Tracker Shows 9 Generic Semaglutide Reviews

Public Tracking System Provides Visibility

The federal regulator's "Generic submissions under review" database allows Canadians to monitor the progress of generic drug applications in real-time. The system lists each submission by company name, drug name, strength, and current review status.

For Ozempic and Wegovy alternatives, the tracker shows applications from multiple pharmaceutical companies seeking to produce generic semaglutide formulations following patent expiry on January 4, 2026.

Multiple Companies Competing for Approval

The tracker reveals generic applications from established pharmaceutical manufacturers including:

• Sandoz Canada: Multiple semaglutide strength formulations
• Apotex Inc.: Various dosage forms under review
• Teva Canada: Generic semaglutide submissions
• Vimy Pharma: Expected to file additional applications in coming weeks
• Other manufacturers: Five additional companies with active submissions

Review Timeline Transparency

The public database shows submission dates and current review phases for each application. Standard generic drug reviews typically take 180 days, though complex biological products like semaglutide may require extended evaluation periods.

Health Canada updates the tracker regularly as applications progress through different review stages. The system indicates whether submissions are under initial review, require additional information, or are approaching final approval decisions.

Manufacturing Readiness Varies

While regulatory approval represents one milestone, several companies have already begun production preparations. Generic semaglutide manufacturing has commenced at Canadian facilities, positioning suppliers for rapid market entry once Health Canada grants approval.

Aspen Pharmacare targets third-quarter 2026 for Canadian market entry, using the country as a reference market for global expansion. Other manufacturers are similarly preparing distribution networks and pricing strategies.

Cost Reduction Expectations

Generic competition typically reduces medication costs by 30-80% compared to brand-name prices. Current Mounjaro and semaglutide products cost $300-400 monthly in Canada without insurance coverage.

Manufacturing cost studies suggest generic semaglutide could be produced for significantly less than current retail prices, though final pharmacy pricing will depend on market competition and regulatory factors.

Patient Access Implications

The tracker helps patients and healthcare providers monitor when lower-cost alternatives might become available. Some online pharmacies have established waitlists for generic semaglutide, anticipating strong demand.

Provincial drug plans and private insurers are watching the approval timeline closely, as generic availability could significantly impact coverage decisions and formulary listings. Use our insurance coverage checker to verify current coverage options.

Regulatory Precedent

Health Canada's public tracking system represents increased transparency in generic drug approvals. The database covers all therapeutic areas, with GLP-1 medications representing some of the most closely watched applications due to high patient demand.

The tracker includes technical details about each submission, including dosage strengths, formulation types, and manufacturing locations. For frequently asked questions about generic medications, visit our FAQ section.